Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KALOS: BGF MDI in Inadequately Controlled Asthma
NCT04609878Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2020
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 21
01
Overview
A Phase 3 trial of glycopyrrolate metered dose inhaler in asthma, sponsored by AstraZeneca. Started Dec 2020; status: completed.
02
Drugs
glycopyrrolate metered dose inhaler
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04609878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04609878.